• 1. Tianjin Medical University First Center Clinical College, Tianjin 300070, P.R. China;
  • 2. Department of Liver Transplantation, Tianjin First Center Hospital; Key Laboratory for Critical Care Medicine of Ministry of Health; Tianjin Key Laboratory for Organ Transplantation; Tianjin Clinical Research Center for Organ Transplantation; Key Laboratory of Transplantation Medicine, Chinese Academy of Medical Sciences, Tianjin 300070, P.R. China;
JIANG Wentao, Email: jiangwentao1974@163.com
Export PDF Favorites Scan Get Citation

Objective  To observe efficacy of rapamycin combined with sorafenib in hepatocellular carcinoma (HCC) patients with tumor recurrence after liver transplantation beyond Milan criteria. Methods  Forty-one beyond Milan criteria HCC patients who underwent the classic orthotopic liver transplantation without bypass and the tumor postoperatively recurred in the Tianjin First Center Hospital from February 1, 2012 to August 31, 2015 were collected retrospectively, then were divided into a local treatment group (n=21) and a comprehensive treatment group (n=20). The local treatment included the surgical resection, radiofrequency ablation, transcatheter arterial chemoembolization, radioactive seed implantation, etc.. The comprehensive treatment was on the basis of the local treatment plus rapamycin in combination with sorafenib. Results  There were 12 patients with stable disease and 9 patients with progressive disease in the local treatment group. There were 12 patients with partial response, 10 patients with stable disease and 8 patients with progressive disease in the comprehensive group. In the local treatment group and the comprehensive treatment group, the median survival time were 9 months and 12 months, and the 1-year and 2-year survival rates after the recurrence were 14% versus 55%, 0 versus 15%, respectively. The survival of the comprehensive treatment group was significantly better than that of the local treatment group (P<0.01). Conclusion  Combination of rapamycin and sorafenib in HCC patients with tumor recurrence after liver transplantation beyond Milan criteria can significantly improve survival time of patient with recurrence.

Citation: GAO Jingya, GUO Qingjun, XIE Yan, ZHANG Li, TIAN Dazhi, LI Junjie, JIANG Wentao. Therapeutic effect of rapamycin combined with sorafenib in hepatocellular carcinoma patients with tumor recurrence after liver transplantation beyond Milan criteria. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2018, 25(9): 1039-1043. doi: 10.7507/1007-9424.201808036 Copy

  • Previous Article

    公民逝世器官捐献肝移植胆道并发症及其预防策略
  • Next Article

    Fully covered self-expandable mental stent in treatment of biliary stricture after liver transplantation